Oral GLP-1 Pills in 2026: What You Can Get Now
The GLP-1 pill is no longer “coming soon.” Two oral weight-loss pills are now FDA-approved — the Wegovy pill and Foundayo — alongside Rybelsus for diabetes. Here’s every oral GLP-1, what it costs, how it compares to the shots, and a straight answer on the “tirzepatide pill.”
The short answer
There are now two FDA-approved oral GLP-1 pills for weight loss: the Wegovy pill (oral semaglutide, launched January 2026, ~$149/mo self-pay, ~16.6% on-treatment weight loss) and Foundayo (orforglipron, approved April 2026, no food/water restrictions). the Ozempic pill is oral semaglutide for type 2 diabetes — the tablets that replaced the Rybelsus brand in the US on May 4, 2026. Tirzepatide (Mounjaro/Zepbound) still has no pill.
Every oral GLP-1 — status, use, and cost
| Oral GLP-1 | Status | Use | Cost | Notes |
|---|---|---|---|---|
| Wegovy pill (oral semaglutide 25 mg) | FDA-approved · launched Jan 2026 | Weight loss + cardiovascular risk | ~$149/mo self-pay | The first oral GLP-1 approved for weight loss. ~16.6% average weight loss on-treatment in OASIS-4 (~13.6% overall), similar to the injection. Self-pay $149/month for the 1.5 mg and 4 mg doses — but Novo states the 4 mg offer runs only to August 31, 2026, then $199/month. Daily tablet taken with a sip of water, then wait 30 minutes to eat. |
| Foundayo (orforglipron, Eli Lilly) | FDA-approved · April 2026 | Weight loss | From $149/mo self-pay · $25 with commercial coverage | A once-daily non-peptide pill — the first GLP-1 with no food, water, or timing restrictions. Self-pay runs $149 (0.8 mg), $199 (2.5 mg) and $299 (5.5 mg and up); the two top doses hold $299 only if you refill within 45 days, otherwise $349. Medicare Part D from $50/mo since July 2026. |
| Rybelsus (oral semaglutide, low dose) | FDA-approved (2019) | Type 2 diabetes | As low as $25/mo with the savings card | The original oral semaglutide. Lower doses (7/14 mg) approved for diabetes, not weight loss; must be taken fasting with a small sip of water. |
| Retatrutide (Eli Lilly) | Investigational (Phase 3) | Weight loss (in trials) | — not approved | A triple agonist with the highest weight loss reported so far (~28% in Phase 3) — but it is an injection, not a pill, and is not approved (NDA expected around end of 2026). |
| Amycretin / danuglipron | Investigational / discontinued | — | — not approved | Novo Nordisk’s amycretin (oral and injectable forms) is in earlier trials; Pfizer’s oral danuglipron was scaled back in 2025 over a safety signal. |
Approval status and pricing as of July 2026 and changing fast — confirm current availability and price with the manufacturer or a provider before relying on it. GLP1Zoom is not a pharmacy.
Is there a Wegovy pill?
Yes — the Wegovy pill (oral semaglutide 25 mg) is FDA-approved and launched in the US in January 2026, with a self-pay price around $149/month and ~16.6% on-treatment (~13.6% overall) average weight loss in trials. It’s the same active ingredient as injectable Wegovy, in daily tablet form. (Rybelsus is the older, diabetes-dose oral semaglutide.)
Compare telehealth providers for GLP-1 treatment
SponsoredSome providers now offer the oral options. Visit a partner to check which GLP-1s they prescribe, pricing, and eligibility — we compare and link, we never sell medication.
Advertising disclosure: we may earn a commission if you sign up through these links, at no extra cost to you — it never affects our rankings. How we make money
Go deeper on oral GLP-1
Before you switch to a pill
Oral and injectable GLP-1s share the same class effects and the boxed warning for thyroid C-cell tumors; the oral semaglutide pill has specific dosing rules (taken with a sip of water, then wait before eating). Retatrutide, amycretin, and danuglipron are not approved — be cautious of anyone selling an “unapproved GLP-1 pill” online. This page is educational, not medical advice; talk to a licensed clinician. GLP1Zoom is an independent comparison site, not a pharmacy.
Common questions about Oral GLP-1
Is there a GLP-1 pill for weight loss?
Yes — as of 2026 there are two FDA-approved oral GLP-1 pills for weight loss: the Wegovy pill (oral semaglutide 25 mg), which launched in the US in January 2026, and Foundayo (orforglipron), approved in April 2026. Oral semaglutide for type 2 diabetes is sold as the Ozempic pill — Novo retired the Rybelsus brand in the US on May 4, 2026 and the tablets 1.5/4/9 mg replace Rybelsus 3/7/14 mg. It is a diabetes medicine, not a weight-loss one. This is general information, not medical advice.
Is there a Wegovy pill, and how much does it cost?
Yes. The Wegovy pill — once-daily oral semaglutide 25 mg — is FDA-approved and launched in the US in January 2026. Novo Nordisk has offered a self-pay price around $149/month through its savings program, and it’s available via retail pharmacies and select telehealth providers. In the OASIS-4 trial it produced about 16.6% average weight loss among adherent participants (~13.6% treatment-policy/overall), similar to the injectable. Confirm current pricing and eligibility before relying on it.
What is Foundayo (orforglipron)?
Foundayo is Eli Lilly’s orforglipron, a once-daily oral GLP-1 pill that the FDA approved in April 2026 for chronic weight management. Unlike oral semaglutide, it’s a non-peptide drug with no food, water, or timing restrictions — you can take it any time. It’s used with a reduced-calorie diet and increased activity.
Is there a tirzepatide pill or oral tirzepatide?
No. Tirzepatide (Mounjaro and Zepbound) remains injection-only, and there is no oral tirzepatide approved or in late-stage trials. If you want a GLP-1 pill, the approved options are the Wegovy pill (oral semaglutide) and Foundayo (orforglipron) — both different from tirzepatide.
Are GLP-1 pills as effective as the injections?
For semaglutide, the oral Wegovy pill produced weight loss (~16.6% on-treatment in OASIS-4; ~13.6% overall) similar to the injectable version. Across all GLP-1s, the strongest weight loss reported to date is still from injectables — tirzepatide (Zepbound) and the investigational retatrutide (~28% in trials, not yet approved). The best option depends on your health, tolerance, and cost; discuss it with a licensed clinician.
How do I get a GLP-1 pill?
All GLP-1 pills are prescription-only. You can get the Wegovy pill or Foundayo (orforglipron) for weight loss, or the Ozempic pill for diabetes (the tablets that replaced Rybelsus in the US), through your doctor or a telehealth provider that evaluates you and prescribes if appropriate. Compare telehealth providers to see who offers the oral options and at what price.
How we sourced this
Status reflects FDA approvals and manufacturer announcements: oral semaglutide / Wegovy pill (Novo Nordisk, FDA-approved 2025, US launch January 2026, OASIS-4 trial) and orforglipron / Foundayo (Eli Lilly, FDA-approved April 2026); retatrutide, amycretin and danuglipron remain investigational as of mid-2026. Pricing and availability change frequently — confirm before acting. Educational information, not medical advice. Last reviewed 2026-06-29.